Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 5
Submit an article Journal homepage
323
Views
14
CrossRef citations to date
0
Altmetric
Letters to the Editor

Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy

Rory M. ShallisDepartment of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; ORCID Iconhttp://orcid.org/0000-0002-8542-2944View further author information
ORCID Icon,
Maximilian StahlDepartment of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; View further author information
,
Wei WeiDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA; View further author information
,
Pau MontesinosCIBERONC, Instituto Carlos III, Madrid, Spain; ORCID Iconhttp://orcid.org/0000-0002-3275-5593View further author information
ORCID Icon,
Etienne LenglineHematology Department, Saint-Louis Hospital AP-HP, Paris, France; View further author information
,
Judith NeukirchenDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; View further author information
,
Vijaya R. BhattFred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; View further author information
,
Mikkael A. SekeresLeukemia Program, Cleveland Clinic, Cleveland, OH, USA; View further author information
,
Amir T. FathiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; View further author information
,
Heiko KonigIndiana University Simon Cancer Center, Indianapolis, IN, USA; View further author information
,
Selina LugerAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; View further author information
,
Irum KhanUniversity of Illinois Cancer Center, Chicago, IL, USA; View further author information
,
Gail J. RobozWeill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA; View further author information
,
Thomas CluzeauCHU of Nice, Hematology Department, Cote d’Azur University, Nice, France; View further author information
,
David Martínez-CuadronCIBERONC, Instituto Carlos III, Madrid, Spain; View further author information
,
Emmanuel RaffouxHematology Department, Saint-Louis Hospital AP-HP, Paris, France; View further author information
,
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; View further author information
,
Jayadev Manikkam UmakanthanUniversity of North Carolina Physician Network, Rocky Mount, NC, USA; View further author information
,
Sudipto MukherejeLeukemia Program, Cleveland Clinic, Cleveland, OH, USA; View further author information
,
Andrew M. BrunnerMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; View further author information
,
Adam MillerIndiana University Simon Cancer Center, Indianapolis, IN, USA; View further author information
,
Christine M. McMahonAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; ORCID Iconhttp://orcid.org/0000-0001-9745-9595View further author information
ORCID Icon,
Ellen K. RitchieWeill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA; View further author information
,
Rebeca Rodríguez-VeigaCIBERONC, Instituto Carlos III, Madrid, Spain; View further author information
,
Raphaël ItzyksonHematology Department, Saint-Louis Hospital AP-HP, Paris, France; View further author information
,
Blanca BoludaCIBERONC, Instituto Carlos III, Madrid, Spain; ORCID Iconhttp://orcid.org/0000-0002-1785-5561View further author information
ORCID Icon,
Florence RabianCIBERONC, Instituto Carlos III, Madrid, Spain; ;Hematology Department, Saint-Louis Hospital AP-HP, Paris, France; View further author information
,
Mar TormoUniversity Clinical Hospital, INCLIVA, Valencia, SpainORCID Iconhttp://orcid.org/0000-0001-9622-1649View further author information
ORCID Icon,
Evelyn Acuña-CruzCIBERONC, Instituto Carlos III, Madrid, Spain; View further author information
,
Emma RabinovichUniversity of Illinois Cancer Center, Chicago, IL, USA; View further author information
,
Brendan YooAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; View further author information
,
Isabel CanoCIBERONC, Instituto Carlos III, Madrid, Spain; View further author information
,
Nikolai A. PodoltsevDepartment of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; View further author information
,
Jan Philipp BewersdorfDepartment of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; ORCID Iconhttp://orcid.org/0000-0003-3352-0902View further author information
ORCID Icon,
Steven GoreDepartment of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; View further author information
&
Amer M. ZeidanDepartment of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; Correspondence[email protected]
View further author information
 show all
Pages 1220-1225 | Received 30 Nov 2019, Accepted 31 Jan 2020, Published online: 26 Feb 2020

References

  • Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246–3252.
  • Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. JCO. 1987;5(9):1364–1372.
  • Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18.
  • Ganzel C, Becker J, Mintz PD, Lazarus HM, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117–122.
  • Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
  • Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98(2):433–436.
  • Thiebaut A, Thomas X, Belhabri A, et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000;79:501–506.
  • Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001;42(1–2):67–73.
  • Nan X, Qin Q, Gentille C, et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis – a retrospective study from a tertiary center. Leuk Lymphoma. 2017;58(9):1–11.
  • Choi MH, Choe YH, Park Y, et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018;58(1):208–216.
  • Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study. Leukemia. 2020. Forthcoming.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
  • Bhatt VR, Shostrom V, Gundabolu K, et al. Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. Blood Adv. 2018;2(11):1277–1282.
  • Zeidan AM, Podoltsev NA, Wang X, et al. Temporal patterns and predictors of receiving no active therapy among older patients with acute myeloid leukemia in the United States: a population level analysis. Cancer. 2019;125(23):4241–4251.
  • Shallis RM, Boddu PC, Bewersdorf JP, et al. The golden age for patients in their golden years: the progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Rev. 2019:100639. DOI:10.1016/j.blre.2019.100639
  • Shelat SG. Practical considerations for planning a therapeutic apheresis procedure. Am J Med. 2010;123(9):777–784.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.